

and physicians about the different needs of subsets of obese individuals is important. The tendency to treat obese individuals with a one-size-fits-all approach will be counterproductive with metabolically healthy but obese people. And in clinical research, data from cohorts mixing at-risk individuals with those with metabolically benign obesity might be difficult to interpret.

Antony D Karelis

Department of Kinesiology, University of Quebec at Montreal, Montreal, QC, Canada H2X 3R9
karelis.antony@uqam.ca

I declare that I have no conflict of interest.

- 1 Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? *J Clin Endocrinol Metab* 2004; **89**: 2569–75.
- 2 Sims EA. Are there persons who are obese, but metabolically healthy? *Metabolism* 2001; **50**: 1499–504.
- 3 Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Prevalence of uncomplicated obesity in an Italian obese population. *Obes Res* 2005; **13**: 1116–22.
- 4 Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. *Arch Intern Med* 2008; **168**: 1609–16.
- 5 Aguilar-Salinas CA, Garcia EG, Robles L, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. *J Clin Endocrinol Metab* 2008; published online Aug 5. DOI:10.1210/jc.2007-2724.
- 6 Brochu M, Tchernof A, Dionne IJ, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? *J Clin Endocrinol Metab* 2001; **86**: 1020–25.
- 7 Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy, but obese individual presents a favorable inflammation profile. *J Clin Endocrinol Metab* 2005; **90**: 4145–50.
- 8 Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. *Diabetes* 1999; **48**: 2210–14.
- 9 Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. *J Clin Endocrinol Metab* 2006; **91**: 2906–12.
- 10 Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). *Arch Intern Med* 2008; **168**: 1617–24.
- 11 Karelis AD, Rabasa-Lhoret R. Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. *Diabetes Metab* 2008; **34**: 183–84.
- 12 Perseghin G. Is a nutritional therapeutic approach unsuitable for metabolically healthy but obese women? *Diabetologia* 2008; **51**: 1567–69.
- 13 Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R. Metabolically healthy but obese women: effect of an energy-restricted diet. *Diabetologia* 2008; **51**: 1752–54.

Collapse of GMC hearing into research misconduct

On July 4, the UK's General Medical Council (GMC) announced that their Professional Conduct Committee had halted a disciplinary hearing into a research study done in Stoke on Trent, Staffordshire, UK, between 1990 and 1993.¹ The study, the CNEP trial, was designed to compare two strategies for supporting the breathing of preterm babies.^{2,3} A complaint about this study had been lodged with the GMC in April, 1997, but a public hearing finally opened only in May, 2008. The main allegations were of failure to obtain informed consent, misleading the research ethics committee, faulty trial design and analysis, and misleading presentation of results.

The GMC put the testimony of three experts before the Panel on behalf of the complainants. Two could find little to fault in the conduct of the study, and the Panel had considerable reservations about whether the third qualified as an expert because he had "little or no formal training in medical ethics" and was no longer on the medical register.¹ The Panel went on: "Furthermore, he has until recently published articles in his *Bulletin of Medical Ethics* and been quoted in the media such as to demonstrate a deep animosity towards Dr David Southall".¹ The ruling continued: "The Panel

does not think that any reasonable Panel could safely rely on his opinion evidence." Hey⁴ has already written, in 2006, that the allegations of consent forms being fabricated were highly implausible. The Panel observed that "given the lapse of time, it could not be proved to the required standard that consent was not taken properly".¹ They dismissed the case against the three doctors after listening to four barristers and 27 witnesses over a period of 8 weeks without even asking to hear what the defence had to say.

The GMC's first task is to protect the public, but the public will not think much of the protection on offer if review sometimes takes 11 years. It has been a costly as well as a lengthy business. The Department of Health will not reveal the cost of the inquiry they commissioned, or admit to its flaws.⁵ Had they done so, the issues before the GMC would certainly have been settled much sooner. The local hospital Trust spent the best part of £1 million dealing with the complaint.⁶ The medical defence societies have spent a similar sum in the past 10 years, and the GMC must have spent a substantial sum preparing its case, appearing in the High Court and the Court of Appeal, and holding its own hearings.

The printed journal includes an image merely for illustration

Rui Vieira/PA Archive/PA Photos

North Staffordshire Hospital, Stoke on Trent, UK

However, there have been a range of even more important intangible costs: to the doctors and nurses under scrutiny and their families, to the faith that the local community has in the care of children going into hospital in Stoke, to neonatal research across the whole of the UK for at least 6 years, and to the faith that doctors, and paediatricians in particular, now have in the competence and fairness of the GMC's handling of allegations of misconduct. The findings of the Department of Health's flawed inquiry were used to support the creation of an additional layer of bureaucracy for clinical research in the UK.

Clinicians are wondering if the GMC is now questioning the validity of consent forms on the basis of what parents can remember 15 years later, even though the forms were signed by a parent and countersigned and dated by a doctor at the time. How is a current researcher supposed to document consent now if this is not thought adequate? In the recent randomised CoolCap⁷ and TOBY⁸ hypothermia trials for term infants with hypoxic-ischaemic encephalopathy, treatment had to be started within 6 h of birth. This timing required recently delivered mothers to read and comprehend the concepts

of secondary brain injury, uncertainty of therapeutic benefit, and random treatment allocation. These things are not always remembered.⁹ Are the investigators of these trials to be subjected to a 2-month legal hearing in 2020?

And who regulates the regulators? To end up having the same basic complaint looked at seven times in 11 years seems to be a gross abuse of process to many of the clinicians involved (and more than ten were under scrutiny at one stage). To have the case collapse in this way certainly suggests a serious and sustained systems failure somewhere within the GMC. Paediatricians elsewhere in the world feel that the drawn-out repeated inquiries suggest a desire to target David Southall, one of the three clinicians in the dock.¹⁰ Lessons certainly need to be learnt.

8 years ago, the editors of *The Lancet* and the *BMJ* said that the UK lacked a robust forum for looking into allegations of research misconduct.¹¹ Such a forum is still lacking, and the GMC has shown that it is not the body to take on this task.

Andrew Whitelaw

Department of Clinical Science at North Bristol, University of Bristol, Bristol BS10 5NB, UK
andrew.whitelaw@bris.ac.uk

AW would have been an expert witness for the defence if the GMC case had not ended early. I thank Edmund Hey for detailed discussions on earlier drafts of this Comment. Edmund Hey has provided free advice to David Southall's lawyers and given personal support to all three defendants.

- 1 General Medical Council. Fitness to practise panel. July 4, 2008. http://www.gmc-uk.org/concerns/hearings_and_decisions/ftp/20080704_ftp_panel_spencer.asp (accessed Aug 2, 2008).
- 2 Samuels MP, Raine J, Wright T, et al. Continuous negative extrathoracic pressure in neonatal respiratory failure. *Pediatrics* 1996; **98**: 1154-60.
- 3 Telford K, Waters L, Vyas H, et al. Outcome following continuous negative extrathoracic pressure ventilation. *Lancet* 2006; **367**: 1080-85.
- 4 Hey E. The 1996 continuous negative extrathoracic pressure (CNEP) trial: were parent's allegations of research fraud fraudulent? *Pediatrics* 2006; **117**: 2244-46.
- 5 Chalmers I, Hey E. Learning from Bristol: the need for a lead from the chief medical officer. *BMJ* 2001; **323**: 280-81.
- 6 Hey E, Fleming P, Sibert J. Learning from the sad, sorry saga at Stoke. *Arch Dis Child* 2002; **86**: 1-3.
- 7 Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. *Lancet* 2005; **365**: 663-67.
- 8 Azzopardi D, Brocklehurst P, Edwards D, et al, and The TOBY Study Group. The TOBY Study. Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy: a randomised controlled trial. *BMC Pediatr* 2008; **8**: 17.
- 9 Stenson BJ, Becher J-C, McIntosh N. Neonatal research: the parental perspective. *Arch Dis Child* 2004; **89**: F321-24.
- 10 Jenny C. The intimidation of British pediatricians. *Pediatrics* 2007; **119**: 797-99.
- 11 Farthing M, Horton R, Smith R. Research misconduct: Britain's failure to act. *BMJ* 2000; **321**: 1485-86.